SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vis…
Month: November 2017
Combination Therapies to Boost the Glaucoma Therapeutics Market | Technavio
LONDON–(BUSINESS WIRE)–#GlaucomaTherapeutics–Technavio market research analysts forecast the global glaucoma therapeutics market to grow at a CAGR of close to 4% during the period 2017-2021.
Researchers predict greater need for low vision services
The exponential growth in the prevalence of low vision with age reflects the increased risk of vision loss as a result of age-related eye disease each year, according to researchers utilizing data from the National Health and Nutrition Examination Surv…
From Data Management to Leader in Healthcare Informatics: Interview with Information Builders’ Michael Corcoran
In an age in which data is generated at faster rates than ever before, the struggle to streamline and interpret the plethora of available information has been the core driver for many business analytics companies. The challenge is arguably more pressing in an environment as complex as a hospital, where data is constantly gathered at […]
Healthcare Analytics at the Information Builders Summit
Every summer the business analytics and data management company, Information Builders, holds a conference to bring together thousands of company employees, representatives from international conglomerates, and a variety of other attendees. With upwards of 140 presentations and technical workshops spanning three days, there is always something to learn for everyone. This year, Medgadget was invited […]
Artificial Beta Cells Can Release Insulin On-Demand
Researchers from the University of North Carolina and North Carolina State University have developed artificial beta cells that can release insulin in response to rising glucose levels in the blood stream. The technology could be used to treat diabetes through subcutaneous injections of the cells into patients, or gradual delivery using a skin patch. The […]
World’s First MRI Compatible Patient Monitor Cleared by FDA
Traditional vital signs monitors found in most patient hospital rooms can’t be taken into the MRI suite, as that may lead to tragicomic consequences. A patient requiring close monitoring has to be transferred to a specialty monitor attached to a heavy cart that prevents it from being sucked into the bore of the MRI’s magnet, […]
FDA approves study of Orion cortical visual prosthesis system
The FDA has granted full approval for the first human clinical feasibility study of the Orion cortical visual prosthesis system, according to a press release from Second Sight Medical Products.
The Orion device converts images captured by a miniature video camera mounted on a patient’s glasses into a series of small electrical pulses, transmitting those pulses to an array of electrodes implanted on the surface of the visual cortex, the release said. This is intended to result in the perception of light patterns.
Two U.S. sites, the University of California at Los Angeles and Baylor
Resumen: BioTime participará en la Jefferies 2017 London Healthcare Conference
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), una empresa biofarmacéutica de estadio clínico que desarrolla y comercializa productos que tratan enfermedades degenerativas, ha anunciado que Adi Mohanty, co CEO, y Russell Skibsted, director financiero, participarán en la Jefferies 2017 London Healthcare Conference que se celebrará los días 15 y 16 de noviembre en Londres, Reino Unido. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La tra
Samenvatting: BioTime neemt deel aan Jefferies London Healthcare Conference 2017
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), een biotechnologisch bedrijf dat focust op de ontwikkeling en vermarkting van producten voor de behandeling van degeneratieve ziekten, heeft vandaag bekendgemaakt dat Adi Mohanty, co…
Diabetic Eye Disease Awareness Month aims to prevent diabetes-related blindness
November is Diabetic Eye Disease Awareness Month, which aims to educate the public on how diabetes affects vision, the types of eye diseases, risk factors and treatment options, according to a press release from Prevent Blindness.Diabetes is the leadin…
$54 Billion Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022” report has been added to Research and Markets’ offering. The global vision care market reached a value of US$ 54 Billion …
VIDEO: Software aids in patient follow-up
NEW YORK ― At OSN New York 2017, Eric D. Donnenfeld, MD, discusses how he has incorporated MDbackline software into his practice to assist with patient follow-up.
Nautic Partners Announces the Formation of Healthy Eyes Advantage, an Independent Alliance Created to Support Eyecare Professionals
PROVIDENCE, R.I. & BOCA RATON, Fla.–(BUSINESS WIRE)–On November 1, 2017, Nautic Partners, LLC (“Nautic”) announced it created Healthy Eyes Advantage (“Healthy Eyes” or “HEA”) in partnership with four industry leading companies to form the largest alliance of eye care professionals (“ECP”) in the country. Healthy Eyes has acquired substantially all the assets of Block Buying Group (“BBG”); C&E Vision Services (“C&E”); HMI, including Red Tray and Club Zero; and Vision West. Together, He
Second Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Company has received full approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The approval allows two U.
Second Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Centers for Medicare & Medicaid Services (CMS) finalized its Medicare hospital outpatient payment rate of $122,500 for the Argus® II Retinal Prosthesis System (Argus II) procedure for calendar year 2018. The payme
BioTime nimmt an der Jefferies 2017 London Healthcare Conference teil
ALAMEDA, Kalifornien–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), ein klinisches Biotechnologie-Unternehmen, das sich auf die Entwicklung und Vermarktung von Produkten zur Behandlung degenerativer Erkrankungen spezialisiert hat, gab heute bekannt, dass Adi Mohanty, Co-Chief Executive Officer und Russell Skibsted, Chief Financial Officer, an der Jefferies 2017 London Healthcare Conference teilnehmen werden, die am 15. und 16. November in London, Vereinigtes Königreich, stattfinden wird.
Riassunto: BioTime parteciperà all’edizione 2017 della Conferenza sulla sanità di Londra organizzata da Jefferies
ALAMEDA, California–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), società operante nel settore delle biotecnologie specializzata in studi clinici in fase avanzata, impegnata nello sviluppo e nella commercializzazione di prodotti per il trattamento delle malattie degenerative, ha annunciato oggi che Adi Mohanty, condirettore generale, e Russell Skibsted, amministratore finanziario, parteciperanno all’edizione 2017 della Conferenza sulla sanità di Londra, organizzata da Jefferies (Jefferi
BioTime participera à la Conférence sur les soins de santé 2017 de Jefferies à Londres
ALAMEDA, Californie–(BUSINESS WIRE)–BioTime, Inc. (NYSE American : BTX), une société de biotechnologie clinique au stade avancé axée sur le développement et la commercialisation de produits ciblant des maladies dégénératives, a annoncé aujourd’hui qu’Adi Mohanty, co-président-directeur général, et Russell Skibsted, directeur financier, participeront à la Conférence sur les soins de santé 2017 de Jefferies à Londres les 15 et 16 novembre , à Londres, au Royaume-Uni. La Conférence sur les soins
BioTime to Participate in the Jefferies 2017 London Healthcare Conference
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive …